Nuzenio

China Nmpa Ind

China Nmpa Ind news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

country 5 latest news signals 5 publisher sources 100/100 entity strength

Latest news

China-ready by design: Leveraging NMPA’s new 30‑working day IND pathway - Pharmaceutical TechnologyPharmaceutical Technology · Fri, 07 Aug 2026 07:23:11 GMT Alphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA - BioPharma APACBioPharma APAC · Wed, 05 Aug 2026 17:59:31 GMT Insilico Medicine secures China NMPA IND clearance for AI-designed NLRP3 inhibitor ISM8969/HT-001 in Parkinson's - DealroomDealroom · Wed, 05 Aug 2026 07:13:43 GMT InSilico Medicine Cayman TopCo Receives NMPA IND Approval for ISM8969/HT-001, Blood-Brain-Barrier-Penetrant NLRP3 Inhibitor Co-Developed with Hygtia Therapeutics Co., Ltd - marketscreener.commarketscreener.com · Mon, 03 Aug 2026 05:21:39 GMT Ractigen Wins Dual U.S.–China IND Clearances for First-in-Class saRNA Eye Therapy RAG-1C - TipRanksTipRanks · Fri, 31 Jul 2026 11:29:51 GMT

Timeline

Fri, 07 Aug 2026 07:23:11 GMTChina-ready by design: Leveraging NMPA’s new 30‑working day IND pathway - Pharmaceutical Technology

Wed, 05 Aug 2026 17:59:31 GMTAlphamab Oncology IND For Dual Payload Bispecific ADC JSKN021 Accepted By China NMPA - BioPharma APAC

Wed, 05 Aug 2026 07:13:43 GMTInsilico Medicine secures China NMPA IND clearance for AI-designed NLRP3 inhibitor ISM8969/HT-001 in Parkinson's - Dealroom

Mon, 03 Aug 2026 05:21:39 GMTInSilico Medicine Cayman TopCo Receives NMPA IND Approval for ISM8969/HT-001, Blood-Brain-Barrier-Penetrant NLRP3 Inhibitor Co-Developed with Hygtia Therapeutics Co., Ltd - marketscreener.com

Fri, 31 Jul 2026 11:29:51 GMTRactigen Wins Dual U.S.–China IND Clearances for First-in-Class saRNA Eye Therapy RAG-1C - TipRanks

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

Leveraging NMPA2 live mentions IND2 live mentions Accepted By China2 live mentions Parkinson2 live mentions InSilico Medicine Cayman2 live mentions TopCo Receives NMPA2 live mentions IND Approval2 live mentions Blood2 live mentions Brain2 live mentions Barrier2 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for China Nmpa Ind.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.